Form 4: Plus Therapeutics CEO Hedrick Acquires Shares and Warrants in Recent Transaction
SEC Form 4
Plus Therapeutics CEO Marc Hedrick recently acquired shares and warrants of the company's common stock.
Summary
- On May 8, 2024, Marc H. Hedrick, the CEO of Plus Therapeutics, acquired 12,255 shares of common stock at a price of $2.04 per share.
- Following this transaction, Hedrick directly owns 12,425 shares of Plus Therapeutics common stock.
- On the same day, Hedrick also acquired 24,510 warrants with an exercise price of $1.79.
- Half of these warrants (12,255) are Series A warrants expiring on May 8, 2029, and the other half (12,255) are Series B warrants expiring one year after the effectiveness of a registration statement covering the resale of the underlying common stock.
- After the transaction, Hedrick directly owns 24,510 warrants.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's acquisition of shares and warrants suggests confidence, but it's a routine transaction disclosure.
Positives
- The CEO's purchase of shares and warrants could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Stakeholder Impact
- The CEO's increased stake in the company could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of the transaction: acquisition of common stock and warrants. |
| 05/08/2029 | Expiration date for Series A warrants. |
| 05/10/2024 | Date of signature for the SEC Form 4 filing. |
Keywords
Plus Therapeutics, Hedrick, CEO, stock, warrants, acquisition, beneficial ownership, PSTV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.